Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Non-Bayesian knowledge propagation using model-based analysis of data from multiple clinical studies.

Jakob Ribbing1, Andrew C Hooker, E Niclas Jonsson

  • 1Department of Pharmaceutical Biosciences, Division of Pharmacokinetics and Drug Therapy, Uppsala University, P.O. Box 591, Uppsala 75124, Sweden. Jakob.Ribbing@pfizer.com

Journal of Pharmacokinetics and Pharmacodynamics
|November 9, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Objective First, Method Second: Why the Estimand Definition Comes First in Pharmacometric Covariate Modeling.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Conditional Versus Unconditional Covariate Effects in Pharmacometric Models: Implications for Interpretation, Communication, and Reporting.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Population Pharmacokinetics and Exposure-Response Model-Based Bayesian Extrapolation of FVC-Based Efficacy Endpoints From Adults to Pediatric Patients Receiving Nintedanib.

CPT: pharmacometrics & systems pharmacology·2025
Same author

Exposure-Efficacy Meta-Model of Nintedanib in Adult Patients With Chronic Fibrosing Interstitial Lung Diseases.

CPT: pharmacometrics & systems pharmacology·2025
Same author

A Pharmacometrics-Informed Trial Simulation Framework for Optimizing Study Designs for Disease-Modifying Treatments in Rare Neurological Disorders.

CPT: pharmacometrics & systems pharmacology·2025
Same author

Comparing randomized trial designs to estimate treatment effect in rare diseases with longitudinal models: a simulation study showcased by Autosomal Recessive Cerebellar Ataxias using the SARA score.

BMC medical research methodology·2025
Same journal

Optimizing Subcutaneous Antibody Dosing Regimens Through Operating Space Maps: rHuPH20 Case Study.

Journal of pharmacokinetics and pharmacodynamics·2026
Same journal

Mechanistic modeling of FcRn-dependent IgG drug interactions: Clinical applications and dosing implications.

Journal of pharmacokinetics and pharmacodynamics·2026
Same journal

Comparing heavy-tailed residual error models for outlier handling in population PK modeling.

Journal of pharmacokinetics and pharmacodynamics·2026
Same journal

Personalized prophylactic therapy optimization in hemophilia A using a hybrid PK-PD-TTE model and deep RL.

Journal of pharmacokinetics and pharmacodynamics·2026
Same journal

Pediatric oral cavity physiologically based pharmacokinetic model to predict pharmacokinetics of mucoadhesive atropine gel to treat sialorrhea.

Journal of pharmacokinetics and pharmacodynamics·2026
Same journal

Exposure-safety analyses of talazoparib in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in the TALAPRO-2 trial.

Journal of pharmacokinetics and pharmacodynamics·2026
See all related articles

Pooling pharmacokinetic study data improves model selection and predictive performance. Merging separate analyses is a viable alternative, while fitting pre-specified models offers speed and efficiency for drug development knowledge propagation.

Area of Science:

  • Pharmacometrics
  • Drug Development
  • Clinical Pharmacology

Background:

  • Efficient drug development requires safe and effective administration strategies.
  • Accumulating knowledge from clinical studies is crucial for informed decision-making.
  • Model-based approaches, particularly in NONMEM, are central to pharmacokinetic analysis.

Purpose of the Study:

  • To investigate various knowledge propagation strategies in pharmacokinetic (PK) studies.
  • To evaluate these strategies using a model-based approach in NONMEM simulations.
  • To compare approaches based on model selection, parameter precision, and predictive performance.

Main Methods:

  • Simulated PK studies under diverse model and design scenarios.
  • Evaluated five knowledge propagation strategies: pooled analysis, merged results, pre-specified model fitting (recent/pooled data), and naive analysis.

Related Experiment Videos

  • Utilized stepwise covariate selection for qualitative knowledge assessment.
  • Assessed quantitative knowledge through parameter precision and model predictive performance.

    • Main Results:

    • Pooling all study data yielded the best model identification and predictive performance.
    • Merging results from separate analyses performed comparably to pooled analysis.
    • Fitting a pre-specified model to all available data was fast and showed improved predictive performance over unbiased alternatives.
    • Pre-specified model fitting on new data is efficient and suitable for confirmatory analyses.

    Conclusions:

    • Pooling pharmacokinetic data is the optimal strategy for robust model identification and prediction.
    • Merging separate analyses offers a strong alternative for knowledge propagation.
    • Fitting pre-specified models to all available data balances speed with strong predictive capabilities.
    • Optimized study designs, including ED-optimal sampling and stratification, enhance sparse data analysis and uncertainty handling.